Business
Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine
First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May 09,
About this update from Humacyte, Inc.
[{"type":"text","content":"First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the publication in The Lancet Regional Health - Europe detailing the encouraging experience of Humacyte’s investigational Human Acellular Vessel (HAV) in treating battlefield and other vascular trauma injuries suffered in Ukraine-Russia conflict. The letter, titled ‘Use of Bioengineered Human Acellular Vessels to Treat Traumatic Injuries in the Ukraine-Russia Conflict’ reports how Ukrainian surgeons have been using Humacyte’s investigational HAV to save life and limb, and provides data on the clinical outcomes of patients treated with the conduit. Humacyte’s initial shipment of HAVs arrived in Ukraine in May 2022, in response to requests from surgeons on the frontlines in that country. Humacyte worked closely with the International Office of the US Food and Drug Administration (FDA) and the Ukrainian Ministry of Health to obtain approval for a humanitarian program, under which Humacyte provided the HAV to hospitals in Ukraine. Additionally, Ukrainian surgeons were virtually trained by video conference to learn the procedures for HAV implantation into patients. Today, the HAV has been used in four hospitals throughout Ukraine. Since June 2022, 18 patients (13 at time of publication submission) in Ukraine have been treated with the HAV to repair vascular trauma and thereby prevent amputation. Three patients received the HAV to treat arterial wounds after failure of their initial vascular repairs using vein or synthetic grafts. Most patients had sustained major vascular injuries to their limbs from blasts and shrapnel on the battlefield. As of April 2023, all HAVs remained patent with no incidents of infection of the conduits, or amputation of the affected limbs. Follow-up procedures post-surgery found no occurrence of mechanical failure in any of the HAVs implanted. “The HAV’s real-world trauma experience in the conflict in Ukraine demonstrates its potential to revolutionize regenerative medicine, and to save life and limb worldwide,” said Laura Niklason, CEO at Humacyte. “Huma...